Schering-Plough’s “Faster” Claims For Lotrimin Ultra Not Accurate – NAD
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough Healthcare Products should modify claims that its Lotrimin Ultra relieves athlete's foot in less time than Novartis Consumer Healthcare's Lamisil Defense, the National Advertising Division recommends
You may also be interested in...
Lamisil Gel Ads Should Emphasize “Between The Toes” Cure Only – NAD
Novartis Consumer Health should modify claims for its Lamisil AT Gel Advanced athlete's foot treatment to emphasize the product has been proven effective in between the toes only, the National Advertising Division states in a decision announced March 3
Lamisil Gel Ads Should Emphasize “Between The Toes” Cure Only – NAD
Novartis Consumer Health should modify claims for its Lamisil AT Gel Advanced athlete's foot treatment to emphasize the product has been proven effective in between the toes only, the National Advertising Division states in a decision announced March 3
Lamisil Gel Ads Should Emphasize “Between The Toes” Cure Only – NAD
Novartis Consumer Health should modify claims for its Lamisil AT Gel Advanced athlete's foot treatment to emphasize the product has been proven effective in between the toes only, the National Advertising Division states in a decision announced March 3